New GERD drug tegoprazan tested in large real-world study

NCT ID NCT07678177

First seen Jul 01, 2026 · Last updated Jul 01, 2026

Summary

This study investigates the safety and symptom-relieving effects of the drug Tegoprazan (K-CAB) in adults with gastroesophageal reflux disease (GERD). Researchers will track how well the drug reduces heartburn and acid reflux after 4 weeks of use. The study includes over 5,000 participants and aims to provide real-world evidence on the drug's performance.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Tegoprazan (K-CAB)

What this could lead to

If successful, this could confirm Tegoprazan as a reliable treatment option for controlling GERD symptoms.

What could go wrong

This is an observational study, not a controlled trial, so results may be less definitive. Individual responses to the drug can vary.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GERD (GASTROESOPHAGEAL REFLUX DISEASE) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

gastroesophageal reflux disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • HK inno.N

    RECRUITING

    Seoul, South Korea

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••